Clavis Pharma To Participate At "Helseseminar Med Fokus På Kreft" Organised By The Norwegian Society Of Financial Analysts

Oslo, Norway, Mar 27, 2008 - (ABN Newswire) - Clavis Pharma ASA (OSLO: CLAVIS) will participate at the Norwegian healthcare seminar "Helseseminar med fokus på kreft" on Friday, 28 March, at 10:00AM at Thon Conference Vika Atrium, Oslo. The seminar is organised by the Norwegian Society of Financial Analysts. Tom Pike, the CEO of Clavis Pharma, will make a presentation on the topic of "Chemotherapy - medical and commercial aspects".

The presentation will be made available at Clavis Pharma's homepage, www.clavispharma.com.

For further information please contact: Gunnar Manum, CFO, Clavis Pharma ASA, tel. +47 24 11 09 50 / +47 951 79 190

****

About Clavis Pharma Clavis Pharma ASA is an oncology focused pharmaceutical company using its proprietary Lipid Vector Technology (LVT) platform to create New Chemical Entities (NCEs), by significantly improving already established drugs. The improvements are achieved by chemically binding specific unsaturated lipids to existing, and well understood, approved pharmaceuticals. Data generated suggests the resulting patentable NCEs offer improved efficacy and reduced side effects through enhanced pharmacokinetic properties, greater tissue penetration and, in many cases, additional modes of action.

Clavis Pharma`s objective is to develop its drug candidates until significant value has been created and proof of principle in man has been shown. For further clinical development and commercialisation of the products, Clavis Pharma will enter into strategic partnerships with established pharmaceutical or biotech companies. The company`s product portfolio includes three new cancer drugs, of which the first ELACYT(TM), is in Clinical Phase II, the second, CP-4126, is in Clinical Phase I, and the third, CP-4200, is in Preclinical Development. Results indicate that these products have promising potential for several cancer indications within solid tumours and leukaemia.

The shares of Clavis Pharma ASA are listed on the Oslo Stock Exchange (ticker: CLAVIS). Additional information on Clavis Pharma can be found at: www.clavispharma.com.

Copyright © Hugin AS 2008. All rights reserved.

Clavis Pharma ASA

http://www.clavispharma.com

ISIN: NO0010308240

Stock Identifier: XOSL.CLAVIS